A detailed history of Susquehanna International Group, LLP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 161,338 shares of SMMT stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
161,338
Previous 230,350 29.96%
Holding current value
$1.22 Million
Previous $601,000 10.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$2.55 - $5.07 $175,980 - $349,890
-69,012 Reduced 29.96%
161,338 $667,000
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.83 $173,644 - $294,260
103,979 Added 82.28%
230,350 $601,000
Q3 2023

Nov 14, 2023

SELL
$1.54 - $2.42 $389,575 - $612,189
-252,971 Reduced 66.69%
126,371 $236,000
Q2 2023

Aug 11, 2023

SELL
$1.32 - $2.81 $1.73 Million - $3.68 Million
-1,309,223 Reduced 77.53%
379,342 $952,000
Q1 2023

May 16, 2023

BUY
$1.38 - $5.41 $1.94 Million - $7.62 Million
1,408,141 Added 502.15%
1,688,565 $2.95 Million
Q4 2022

Feb 14, 2023

BUY
$0.68 - $5.31 $135,127 - $1.06 Million
198,717 Added 243.21%
280,424 $1.19 Million
Q3 2022

Nov 14, 2022

BUY
$0.89 - $1.63 $51,682 - $94,654
58,070 Added 245.67%
81,707 $97,000
Q2 2022

Aug 15, 2022

BUY
$0.92 - $2.38 $21,746 - $56,256
23,637 New
23,637 $24,000
Q1 2022

May 16, 2022

SELL
$2.0 - $3.45 $28,922 - $49,890
-14,461 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.45 - $5.64 $4,020 - $9,255
1,641 Added 12.8%
14,461 $39,000
Q3 2021

Nov 15, 2021

SELL
$4.83 - $8.27 $584,372 - $1 Million
-120,988 Reduced 90.42%
12,820 $64,000
Q1 2021

May 17, 2021

BUY
$5.17 - $11.19 $547,616 - $1.19 Million
105,922 Added 379.84%
133,808 $785,000
Q4 2020

Feb 16, 2021

BUY
$3.25 - $6.0 $90,629 - $167,316
27,886 New
27,886 $131,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $1.52B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.